We narrowed to 8,869 results for: aav

#213936-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiPVe4_dTomato_nlsdTomato (#213936). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the chandelier cell-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213829-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiCHATe27_dTomato_nlsdTomato (#213829). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the cholinergic neuron-targeting enhancer E27. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#214147-AAV5

Ready-to-use AAV5 particles produced from pAAV-hIBA1a-GFP-miR124T (#214147). In addition to the viral particles, you will also receive purified pAAV-hIBA1a-GFP-miR124T plasmid DNA. hIBA1a-driven and miR124T-targeted for microglial inhibition of GFP. These AAV preparations are suitable purity for injection into animals.

Chun-Li Zhang

Serrano et al iScience. 2024 Aug 12;27(9):110706. doi:

Sept. 22, 2025

Academic Institutions and Nonprofits only

#202199-AAV1

Ready-to-use AAV1 particles produced from pAAV_hSyn-SIO-stChrimsonR-EGFP-P2A-PdCO-miniWPRE (#202199). In addition to the viral particles, you will also receive purified pAAV_hSyn-SIO-stChrimsonR-EGFP-P2A-PdCO-miniWPRE plasmid DNA. Synapsin-driven, Cre-dependent expression of bicistronically soma-targeted ChrimsonR in frame with EGFP and the optimized opsin PdCO. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

April 10, 2024

Academic Institutions and Nonprofits only

#83894-AAV5

Ready-to-use AAV5 particles produced from pAAV-hDlx-Flex-dTomato-Fishell_7 (#83894). In addition to the viral particles, you will also receive purified pAAV-hDlx-Flex-dTomato-Fishell_7 plasmid DNA. hDlx-driven, Cre-dependent expression of dTomato. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Sept. 27, 2023

Academic Institutions and Nonprofits only

#83895-AAV8

Ready-to-use AAV8 particles produced from pAAV-hDlx-Flex-GFP-Fishell_6 (#83895). In addition to the viral particles, you will also receive purified pAAV-hDlx-Flex-GFP-Fishell_6 plasmid DNA. hDlx-driven, Cre-dependent expression of GFP. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

May 22, 2023

Academic Institutions and Nonprofits only

#117382-AAV2

Ready-to-use AAV2 particles produced from pAAV-hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified pAAV-hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

Feb. 14, 2022

Academic Institutions and Nonprofits only

#117382-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified pAAV-hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

Jan. 6, 2022

Academic Institutions and Nonprofits only

#135633-AAV1

Ready-to-use AAV1 particles produced from pAAV-S5E2-C1V1-eYFP (#135633). In addition to the viral particles, you will also receive purified pAAV-S5E2-C1V1-eYFP plasmid DNA. Expression of red-shifted opsin C1V1 fused to EYFP under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Aug. 27, 2021

Academic Institutions and Nonprofits only

#55638-AAV8

Ready-to-use AAV8 particles produced from pAAV-EF1a-vCre (#55638). In addition to the viral particles, you will also receive purified pAAV-EF1a-vCre plasmid DNA. EF1a-driven expression of VCre. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Nov. 12, 2020

Academic Institutions and Nonprofits only

#232837-AAV8

Ready-to-use AAV8 particles produced from pAAV-Syn-NES-SomaFRCaMPi (#232837). In addition to the viral particles, you will also receive purified pAAV-Syn-NES-SomaFRCaMPi plasmid DNA. Synapsin-driven SomaFRCaMPi calcium sensor. These AAV preparations are suitable purity for injection into animals.

Kiryl Piatkevich

Zhou et al PLoS Biol. 2025 Apr 29;23(4):e3003048. d

Jan. 15, 2026

Academic Institutions and Nonprofits only

#232352-AAV5

Ready-to-use AAV5 particles produced from pAAV-DIO-ATLASsnFlp (#232352). In addition to the viral particles, you will also receive purified pAAV-DIO-ATLASsnFlp plasmid DNA. Syn-driven, ATLASsnFlp expression. These AAV preparations are suitable purity for injection into animals.

Don Arnold

Rivera et al Nat Methods. 2025 May;22(5):1101-1111. d

Jan. 14, 2026

Academic Institutions and Nonprofits only

#170163-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-DIO-ChroME2s-ST-P2A-H2B-mRuby3 (#170163). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-ChroME2s-ST-P2A-H2B-mRuby3 plasmid DNA. CAG-driven, Cre-dependent ChroME2s-ST-P2A-H2B-mRuby3 expression. These AAV preparations are suitable purity for injection into animals.

Hillel Adesnik

Sridharan et al Neuron. 2022 Jan 27. pii: S0896-6273(22)

Nov. 13, 2025

Academic Institutions and Nonprofits only

#213833-AAV5

Ready-to-use AAV5 particles produced from pAAV_BiCHATe27_GCaMP6f (#213833). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the cholinergic neuron-targeting enhancer E27. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Nov. 13, 2025

Academic Institutions and Nonprofits only

#203840-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-Kir2.1WT-2A-mScarlet-KASH (#203840). In addition to the viral particles, you will also receive purified pAAV-hSyn-Kir2.1WT-2A-mScarlet-KASH plasmid DNA. hSyn-driven expression of Kir2.1 and mScarlet-KASH. These AAV preparations are suitable purity for injection into animals.

Ivo Spiegel

Roethler et al Neuron. 2023 Jun 20:S0896-6273(23)00399-

Oct. 8, 2025

Academic Institutions and Nonprofits only

#213830-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiCHATe27_ChR2_mCherry (#213830). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the cholinergic neuron-targeting enhancer E27. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#50465-AAV11

Ready-to-use AAV11 particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

July 16, 2025

Academic Institutions and Nonprofits only

#198510-AAV1

Ready-to-use AAV1 particles produced from pAAV_hSyn-PdCO-mScarlet-WPRE (#198510). In addition to the viral particles, you will also receive purified pAAV_hSyn-PdCO-mScarlet-WPRE plasmid DNA. Syn-driven expression of optimized PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

Jan. 27, 2025

Academic Institutions and Nonprofits only

#183519-AAV8

Ready-to-use AAV8 particles produced from pAAV-CaMKIIa-ChRmine-oScarlet-KV 2.1-WPRE (#183519). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-ChRmine-oScarlet-KV 2.1-WPRE plasmid DNA. CaMKIIa-driven expression of ChRmine-oScarlet-KV 2.1. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Kishi et al Cell. 2022 Feb 17;185(4):672-689.e23. do

Dec. 18, 2024

Academic Institutions and Nonprofits only

#198510-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn-PdCO-mScarlet-WPRE (#198510). In addition to the viral particles, you will also receive purified pAAV_hSyn-PdCO-mScarlet-WPRE plasmid DNA. Syn-driven expression of optimized PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

Sept. 27, 2024

Academic Institutions and Nonprofits only

#198516-AAV1

Ready-to-use AAV1 particles produced from pAAV_EF1a-DIO-PdCO-mScarlet-ER-miniWPRE (#198516). In addition to the viral particles, you will also receive purified pAAV_EF1a-DIO-PdCO-mScarlet-ER-miniWPRE plasmid DNA. Ef1a-driven, Cre-dependent expression of the optimized opsin PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

April 10, 2024

Academic Institutions and Nonprofits only

#104055-AAV2

Ready-to-use AAV2 particles produced from pAAV-CAG-eYFP (#104055). In addition to the viral particles, you will also receive purified pAAV-CAG-eYFP plasmid DNA. CAG-driven eYFP expression control. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

June 13, 2023

Academic Institutions and Nonprofits only

#83895-AAV2

Ready-to-use AAV2 particles produced from pAAV-hDlx-Flex-GFP-Fishell_6 (#83895). In addition to the viral particles, you will also receive purified pAAV-hDlx-Flex-GFP-Fishell_6 plasmid DNA. hDlx-driven, Cre-dependent expression of GFP. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Jan. 6, 2022

Academic Institutions and Nonprofits only

#153285-AAV1

Ready-to-use AAV1 particles produced from pAAV-hsyn-GRAB_Ado1.0 (#153285). In addition to the viral particles, you will also receive purified pAAV-hsyn-GRAB_Ado1.0 plasmid DNA. hSyn-driven expression of GRAB_Ado1.0 adenosine sensor in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Peng et al Science. 2020 Sep 4;369(6508). pii: 369/

Feb. 9, 2026

Academic Institutions and Nonprofits only

#140275-AAV1

Ready-to-use AAV1 particles produced from pAAV-N-RAM-d2tTA-TRE-mKate2 (#140275). In addition to the viral particles, you will also receive purified pAAV-N-RAM-d2tTA-TRE-mKate2 plasmid DNA. RAM-containing and TRE-driven expression of mKate2. These AAV preparations are suitable purity for injection into animals.

Yingxi Lin

Sun et al Cell. 2020 Apr 16;181(2):410-423.e17. do

Jan. 15, 2026

Academic Institutions and Nonprofits only

#79871-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO_EGFP-GFE3 (#79871). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO_EGFP-GFE3 plasmid DNA. EF1a-driven, Cre-dependent expression of GFP-GFE3. These AAV preparations are suitable purity for injection into animals.

Don Arnold

Gross et al Nat Methods. 2016 Jun 6. doi: 10.1038/nm

Nov. 13, 2025

Academic Institutions and Nonprofits only

#214865-AAV1

Ready-to-use AAV1 particles produced from AiP14871: pAAV-AiE0779m_3xC2-minBG-RiboL1-jGCaMP8s-WPRE3-BGHpA (Alias: CN4871) (#214865). In addition to the viral particles, you will also receive purified AiP14871: pAAV-AiE0779m_3xC2-minBG-RiboL1-jGCaMP8s-WPRE3-BGHpA (Alias: CN4871) plasmid DNA. Neuronal expression of soma-targeted (RL-10, ribosomal tag) jGCaMP8s under the minBG promoter. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

Nov. 13, 2025

Academic Institutions and Nonprofits only

#213937-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiPVe4_ChR2_mCherry (#213937). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the chandelier cell-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213859-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiVIPe4_GCaMP6f (#213859). In addition to the viral particles, you will also receive purified pAAV_BiVIPe4_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the VIP interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213855-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiVIPe4_dTomato_nlsdTomato (#213855). In addition to the viral particles, you will also receive purified pAAV_BiVIPe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the VIP interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213818-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiSSTe10_GCaMP6f (#213818). In addition to the viral particles, you will also receive purified pAAV_BiSSTe10_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the SST interneuron-targeting enhancer E10. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213947-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiSSTe4_GCaMP6f (#213947). In addition to the viral particles, you will also receive purified pAAV_BiSSTe4_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the SST interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#50465-AAV11.T

Ready-to-use AAV11 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

July 16, 2025

Academic Institutions and Nonprofits only

#197200-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-emiRFP670 (#197200). In addition to the viral particles, you will also receive purified pAAV-CAG-emiRFP670 plasmid DNA. CAG-driven expression of emiRFP670. These AAV preparations are suitable purity for injection into animals.

Kiryl Piatkevich

Zhang et al Nat Methods. 2023 Sep 4. doi: 10.1038/s4

Feb. 7, 2025

Academic Institutions and Nonprofits only

#83900-AAV8

Ready-to-use AAV8 particles produced from pAAV-mDlx-GFP-Fishell-1 (#83900). In addition to the viral particles, you will also receive purified pAAV-mDlx-GFP-Fishell-1 plasmid DNA. mDlx-driven expression of GFP in GABA-ergic interneurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

May 22, 2023

Academic Institutions and Nonprofits only

#140137-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-iFlpV (#140137). In addition to the viral particles, you will also receive purified pAAV-EF1a-iFlpV plasmid DNA. EF1a-driven, light-inducible iFlpV recombinase for spatiotemporally precise optogenomic modifications. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Yao et al Nat Methods. 2020 Mar 23. pii: 10.1038/s

Oct. 28, 2021

Academic Institutions and Nonprofits only

#138327-AAV1

Ready-to-use AAV1 particles produced from pAAV-synapsin-HaloCaMP1a-EGFP (#138327). In addition to the viral particles, you will also receive purified pAAV-synapsin-HaloCaMP1a-EGFP plasmid DNA. Synapsin-driven HaloCaMP1a, a far-red calcium sensor, fused to EGFP. These AAV preparations are suitable purity for injection into animals.

Eric Schreiter

Deo et al Nat Chem Biol. 2021 Jun;17(6):718-723. d

Sept. 15, 2021

Academic Institutions and Nonprofits only